odine-meta-iodobenzylguanidine ( 123 I-MIBG) scintigraphy enables visualization of cardiac sympathetic innervation by providing (semi-) quantitative information of the myocardial sympathetic activity (1) . From the early and late planar 123 I-MIBG images the heart-to-mediastinum (H/M) ratio can be obtained. This parameter represents the relative distribution of cardiac sympathetic nerve terminals and offers information about the neuronal function. In addition, the washout rate of the tracer between the early and late planar image can be gained providing information about the sympathetic drive. Furthermore, focal innervation defects can be detected with 123 I-MIBG single photon emission computed tomography (SPECT) (2) .
Cardiac 123 I-MIBG scintigraphy is a well-known technique
for the determination of prognosis in patients with heart failure (3). The late H/M ratio and washout rate appeared to be powerful predictors of survival and ventricular arrhythmias (4) . In addition, 123 I-MIBG imaging can be used to monitor the effect of medical therapy (5) . Therefore, the nuclear cardiology guidelines of the Japanese Circulation Society recommend cardiac 123 I-MIBG in heart failure patients for assessment of heart failure severity and prognosis (6) . Outside Japan the use of cardiac 123 I-MIBG scintigraphy is low in clinical practice since it has not been implemented in clinical guidelines (7, 8) . In addition, there is a lack of standardization and validation of cardiac 123 I-MIBG imaging and postprocessing procedures (9) . As well as the limited gains in costeffectiveness and the long awaited FDA approval in the USA (10 
Cardiac diseases beyond heart failure

Myocardial infarction
The autonomic function in patients after an acute myocardial infarction (AMI) can be disturbed since damaged (46) . As a consequence, the five-year mortality risk in patients with a late H/M ratio < 1. 60 was 6-fold higher compared with patients with a late H/M ratio ≥1.60.
Cardiovascular risk factors
Diabetes Mellitus
The prevalence of DM is increasing in the western world, by evaluation with heart rate variability, 58% versus 27%, respectively (17).
In addition, in patients with heart failure and DM the H/M ratio is significantly lower than in patients without DM (48, 52) . Furthermore, patients with heart failure and DM with a H/M ratio <1.6 are at 3-fold higher 2-years risk of heart failure progression compared with patients with a late H/M ratio ≥1.6
(52).
Resistant hypertension
If the blood pressure remains too high regardless of three antihypertensive medications out of different classes or controlled with four or more agents, and secondary hypertension is excluded, resistant hypertension should be considered (53) . It is important to treat resistant hypertension since it is a powerful predictor for cardiovascular morbidity and mortality. Therefore, the precise role in renal denervation needs to be further evaluated in larger studies. 
Heart transplantation and left ventricular assist device implantation
Complete denervation of the allograft occurs after heart transplantation. In some patients the catecholamine storage capacity is regained which is associated with improved response of the heart rate and contractile function to exercise (67) . However, this is a slow process that takes often more than 1 year up to even 12 years and can be demonstrated by 123 I-MIBG imaging (13, 68) . In addition, patients with idiopathic cardiomyopathy are less likely to re-gain innervation compared to other aetiologies of congestive heart failure, as well as in patients with DM (69).
Patients pending on or non-eligible for a heart transplantation can nowadays be treated with a left ventricular assist device (LVAD) to reduce mortality and improve quality of life. To evaluate the effects of LVAD on cardiac sympathetic innervation 123 I-MIBG imaging has demonstrated that after LVAD implantation the early and late H/M ratio increases and the washout rate decreases (70, 71) .
Conclusion
This review provides an overview of the potential increasing number of clinical indications of cardiac 123 I-MIBG imaging besides heart failure in the last few years.
However, first cardiac 123 I-MIBG has to be implemented in heart failure guidelines outside Japan, before other potential indications will. Until then other indications beyond heart failure will stay pre-clinical.
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